Article Versions Notes

Chang G-R, Hou P-H, Wang C-M, Lin J-W, Lin W-L, Lin T-C, Liao H-J, Chan C-H, Wang Y-C. Imipramine Accelerates Nonalcoholic Fatty Liver Disease, Renal Impairment, Diabetic Retinopathy, Insulin Resistance, and Urinary Chromium Loss in Obese Mice. Veterinary Sciences. 2021; 8(9):189. https://doi.org/10.3390/vetsci8090189

Chang, Geng-Ruei, Po-Hsun Hou, Chao-Min Wang, Jen-Wei Lin, Wei-Li Lin, Tzu-Chun Lin, Huei-Jyuan Liao, Chee-Hong Chan, and Yu-Chen Wang. 2021. "Imipramine Accelerates Nonalcoholic Fatty Liver Disease, Renal Impairment, Diabetic Retinopathy, Insulin Resistance, and Urinary Chromium Loss in Obese Mice" Veterinary Sciences 8, no. 9: 189. https://doi.org/10.3390/vetsci8090189

Chang, G. -R., Hou, P. -H., Wang, C. -M., Lin, J. -W., Lin, W. -L., Lin, T. -C., Liao, H. -J., Chan, C. -H., & Wang, Y. -C. (2021). Imipramine Accelerates Nonalcoholic Fatty Liver Disease, Renal Impairment, Diabetic Retinopathy, Insulin Resistance, and Urinary Chromium Loss in Obese Mice. Veterinary Sciences, 8(9), 189. https://doi.org/10.3390/vetsci8090189